Literature DB >> 26912625

Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Alexander J McAuley1,2, Maricela Torres1, Jessica A Plante2,3, Claire Y-H Huang4, Dennis A Bente1,2,5,6, David W C Beasley7,2,5,6.   

Abstract

UNLABELLED: Flaviviruses are positive-sense, single-stranded RNA viruses responsible for millions of human infections annually. The envelope (E) protein of flaviviruses comprises three structural domains, of which domain III (EIII) represents a discrete subunit. The EIII gene sequence typically encodes epitopes recognized by virus-specific, potently neutralizing antibodies, and EIII is believed to play a major role in receptor binding. In order to assess potential interactions between EIII and the remainder of the E protein and to assess the effects of EIII sequence substitutions on the antigenicity, growth, and virulence of a representative flavivirus, chimeric viruses were generated using the West Nile virus (WNV) infectious clone, into which EIIIs from nine flaviviruses with various levels of genetic diversity from WNV were substituted. Of the constructs tested, chimeras containing EIIIs from Koutango virus (KOUV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV), and Bagaza virus (BAGV) were successfully recovered. Characterization of the chimeras in vitro and in vivo revealed differences in growth and virulence between the viruses, within vivo pathogenesis often not being correlated within vitro growth. Taken together, the data demonstrate that substitutions of EIII can allow the generation of viable chimeric viruses with significantly altered antigenicity and virulence. IMPORTANCE: The envelope (E) glycoprotein is the major protein present on the surface of flavivirus virions and is responsible for mediating virus binding and entry into target cells. Several viable West Nile virus (WNV) variants with chimeric E proteins in which the putative receptor-binding domain (EIII) sequences of other mosquito-borne flaviviruses were substituted in place of the WNV EIII were recovered, although the substitution of several more divergent EIII sequences was not tolerated. The differences in virulence and tissue tropism observed with the chimeric viruses indicate a significant role for this sequence in determining the pathogenesis of the virus within the mammalian host. Our studies demonstrate that these chimeras are viable and suggest that such recombinant viruses may be useful for investigation of domain-specific antibody responses and the more extensive definition of the contributions of EIII to the tropism and pathogenesis of WNV or other flaviviruses.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26912625      PMCID: PMC4836310          DOI: 10.1128/JVI.02861-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.

Authors:  S L Allison; J Schalich; K Stiasny; C W Mandl; F X Heinz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses.

Authors:  P S Caufour; M C Motta; A M Yamamura; S Vazquez; I I Ferreira; A V Jabor; M C Bonaldo; M S Freire; R Galler
Journal:  Virus Res       Date:  2001-11-05       Impact factor: 3.303

6.  Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry.

Authors:  E Lee; M Lobigs
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice.

Authors:  W Chen; H Kawano; R Men; D Clark; C J Lai
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Comparing competitive fitness of West Nile virus strains in avian and mosquito hosts.

Authors:  Gabriella Worwa; Sarah S Wheeler; Aaron C Brault; William K Reisen
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

9.  A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.

Authors:  E N Gallichotte; D G Widman; B L Yount; W M Wahala; A Durbin; S Whitehead; C A Sariol; J E Crowe; A M de Silva; R S Baric
Journal:  mBio       Date:  2015-10-13       Impact factor: 7.867

Review 10.  Yellow fever vector live-virus vaccines: West Nile virus vaccine development.

Authors:  J Arroyo; C A Miller; J Catalan; T P Monath
Journal:  Trends Mol Med       Date:  2001-08       Impact factor: 11.951

View more
  6 in total

1.  Chimeric Zika viruses containing structural protein genes of insect-specific flaviviruses cannot replicate in vertebrate cells due to entry and post-translational restrictions.

Authors:  Chandra S Tangudu; Jermilia Charles; Daniel Nunez-Avellaneda; Alissa M Hargett; Aaron C Brault; Bradley J Blitvich
Journal:  Virology       Date:  2021-03-26       Impact factor: 3.513

Review 2.  Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections.

Authors:  Xingcui Zhang; Renyong Jia; Haoyue Shen; Mingshu Wang; Zhongqiong Yin; Anchun Cheng
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

3.  Quasispecies composition and evolution of a typical Zika virus clinical isolate from Suriname.

Authors:  Sander van Boheemen; Ali Tas; S Yahya Anvar; Rebecca van Grootveld; Irina C Albulescu; Martijn P Bauer; Mariet C Feltkamp; Peter J Bredenbeek; Martijn J van Hemert
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

4.  Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.

Authors:  Emily N Gallichotte; Ellen F Young; Thomas J Baric; Boyd L Yount; Stefan W Metz; Matthew C Begley; Aravinda M de Silva; Ralph S Baric
Journal:  mBio       Date:  2019-09-17       Impact factor: 7.867

5.  Neuroinvasiveness of the MR766 strain of Zika virus in IFNAR-/- mice maps to prM residues conserved amongst African genotype viruses.

Authors:  Eri Nakayama; Fumihiro Kato; Shigeru Tajima; Shinya Ogawa; Kexin Yan; Kenta Takahashi; Yuko Sato; Tadaki Suzuki; Yasuhiro Kawai; Takuya Inagaki; Satoshi Taniguchi; Thuy T Le; Bing Tang; Natalie A Prow; Akihiko Uda; Takahiro Maeki; Chang-Kweng Lim; Alexander A Khromykh; Andreas Suhrbier; Masayuki Saijo
Journal:  PLoS Pathog       Date:  2021-07-26       Impact factor: 6.823

6.  Characteristics of Chimeric West Nile Virus Based on the Japanese Encephalitis Virus SA14-14-2 Backbone.

Authors:  Guohua Li; Xianyong Meng; Zhiguang Ren; Entao Li; Feihu Yan; Jing Liu; Ying Zhang; Zhanding Cui; Yuetao Li; Hongli Jin; Zengguo Cao; Le Yi; Pei Huang; Hang Chi; Hualei Wang; Weiyang Sun; Tiecheng Wang; Yuwei Gao; Yongkun Zhao; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.